SLA already has regulatory approval to sell Roproen as a pharmaceutical in Russia.
The real issue is that they haven't released enough data to prove that it does what they say it does. They may have the data, but they haven't released it. Pretty much every other company that is involved in pharmaceutical development releases enough data to demonstrate thet their products do what they say they do, big or small.
So in the absence of proof that Ropren does what they say it does, you need to ask yourself, "does what they say sound plausible?". For it to be plausible, you need to see how the drug might actually work. Thus, you end up looking at dolichols.
If you haven't invested in a biotech before and would like to, I suggest you take a small stake in one (you always learn more when you have skin in the game) and treat it as a learning experience. Once you have the knack of it, then you can take more exposure.
Cheers,
Bill
SLA Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)